FDA Places Clinical Hold on Scynexis’ IV Antifungal, Lifts Hold on Seattle Genetics AML Treatment

Drug Industry Daily
A A
The FDA has asked Scynexis to hold new clinical studies of an intravenous formulation of its antifungal treatment, SCY-078, until the agency can review available pre-clinical and clinical data.

To View This Article:

Login

Subscribe To Drug Industry Daily